Melanoma Peptide-Loaded Dendritic Cell Vaccine in HLA-A 0201 Patients With Stage IV Melanoma: A Phase II Randomized Trial to Compare Vaccination With and Without Cyclophosphamide Treatment.
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2013
At a glance
- Drugs Cyclophosphamide (Primary) ; ODC 0501 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 05 Jul 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 16 Sep 2010 Planned end date changed from 1 Jun 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.